Table 2

Characteristics of patients with PMR after ICI treatment for cancer

Patients	Sex/age, years	Type of cancer	ICI	Date of first ICI exposure	Date of IrAE	Type of rheumatic IrAE	IrAE response to treatment	Autoantibody results	Tumour response
7	F 76	Mesothelioma	Anti-PDL1	June 2014	March 2015	PMR	Resolution with prednisone 20 mg/day then tapered	ANA, RF, CCP negative	Progression switch for pemetrexed
8	M 69	Gastric adenocarcinoma	Pembrolizumab	September 2016	October 2016	PMR	Resolution with prednisone 20 mg/day then tapered	ANA, RF, CCP negative	Progression
9	M 62	Colon adenocarcinoma	Nivolumab+ipilimumab (four cycles) then nivolumab alone	June 2015	October 2015	PMR	Resolution with prednisone 60 mg/day then tapered	ANA 1:320 with anti-ENA negative, RF, CCP negative	Stable disease
10	M 68	Metastatic melanoma	Nivolumab	August 2016	August 2016	PMR	Resolution with prednisone 40 mg/day then tapered	RF, CCP negative	Stable disease

ANA, antinuclear antibodies; anti-ENA, anti-extractable antibodies; CCP, cyclic citrullinated peptide; F, female; ICI, immune checkpoint inhibitor; IrAE, immune-related adverse event; M, male; PDL1, programmed cell death ligand protein 1; PMR, polymyalgia rheumatica; RF, rheumatoid factor.